Prospective study including women aged 25-45 years, adherent to the cervical screening program of four different centers of the Veneto region, with a diagnosis of CIN2 lesion. After enrollment according to predefined criteria, and informed consent to participate, the CIN2 lesions are managed by follow-up; cases with progressive lesions will be treated immediately, cases with CIN2 persistence for more than 12 months will be treated as well. Viral, molecular and immunocytochemical biomarkers will be studied, and evaluated in relation to the clinical outcome.
Women aged 25-45 years, adherent to the organized population-based cervical screening program, with a histological diagnosis of CIN2 and fulfilling the inclusion criteria will be invited to participate to the study, previously providing specific information; in case of acceptance, informed consent is signed. STUDY PROTOCOL: The adherent women will attend periodical control visits: * every 6 months up to 24 months, with performance of: pap test (PT) and colposcopy (with biopsy in case of visible alterations); * at 6 and 12 months control visit: a liquid-based sample of cervical cells will be collected for the biomarkers' analyses. BIOMARKERS: 1. \- HPV search and partial HPV16/18 genotyping, by cobas 4800 high-risk HPV assay (Roche); PCR with MY09/MY11 consensus primers and full genotyping by restriction fragment length analysis, plus PCR with beta-globin primers (in-house); 2. \- methylation analysis of the cellular genes FAM194A and hsa-mir124-2, by methylation-specific quantitative PCR test (qMSP - QIAsure methylation test, Qiagen); 3. \- methylation analysis of the L1 and L2 viral genes of HPV types 16 and 18, by pyrosequencing; 4. \- immunocytochemical analysis for p16INK4A/Ki67 proteins (dual stain), by p16INK4A/Ki67 immunocytochemical analysis by CINtec Plus kit (Roche).
Study Type
OBSERVATIONAL
Enrollment
319
Azienda ULSS 6 Euganea
Padua, PD, Italy
Azienda ULSS 2 Marca Trevigiana
Treviso, TV, Italy
Azienda ULSS 3 Serenissima
Mestre, VE, Italy
Azienda ULSS 9 Scaligera
Verona, VR, Italy
Rate of spontaneous regression of CIN2 lesions
Eligible women will not be treated at diagnosis, but periodically followed-up. Treatment will be provided for progressive lesions and lesions persisting more than 12 months. The rates of lesion regression will be calculated: number of lesions regressed to CIN1 or normal / total number of cases.
Time frame: Through study completion, an average of 2 years.
CIN2 clinical outcome by HPV genotype
Rate of CIN2 regression will be calculated in relation to positivity for HPV16 vs positivity for other high-risk types (number of regressed HPV16-related CIN2 lesions / total number of HPV16-related CIN2 vs number of regressed non-HPV16-related CIN2 lesions / total number of non-HPV16-related CIN2 lesions).
Time frame: Through study completion, an average of 2 years.
CIN2 clinical outcome by DNA methylation
Rate of CIN2 regression will be calculated in relation to DNA methylation of cellular and viral genes (number of regressed hypermethylated CIN2 lesions / total number of CIN2 lesions with valid result for each gene analyzed).
Time frame: Through study completion, an average of 2 years.
CIN2 clinical outcome by p16/ki67 protein expression
Rate of CIN2 regression will be calculated in relation to positivity for p16/ki67 expression (number of regressed p16/ki67-positive CIN2 lesions / total number of CIN2 lesions with valid result for p16/ki67 expression).
Time frame: Through study completion, an average of 2 years.
Adhesion to CIN2 conservative management.
The rate of eligible women consenting to participate to the study will be calculated (enrolled women / eligible women)
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.